Prevention of simian immunodeficiency virus, SIVsm, or HIV‐2 infection in cynomolgus monkeys by pre‐ and postexposure administration of BEA‐005

No abstract is available for this paper.

• Publication year

  1997

• Venue

  AIDS (London)

• Publication date

  1997-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00002030-199702000-00004PMID 9030361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protection against Mucosal SIVsm Challenge in Macaques Infected with a Chimeric SIV that Expresses HIV Type 1 Envelope

  1996cited by this paper
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

  1995cited by this paper
• Viral dynamics in human immunodeficiency virus type 1 infection

  1995cited by this paper
• Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS

  1995cited by this paper
• Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine

  1995influential reference
• Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys

  1994cited by this paper
• An Animal Model for Antilentiviral Therapy: Effect of Zidovudine on Viral Load during Acute Infection after Exposure of Macaques to Simian Immunodeficiency Virus

  1994cited by this paper
• Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study.

  1994influential reference
• Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus.

  1993cited by this paper
• Prevention of HIV-2 and SIV Infections in Cynomolgus Macaques by Prophylactic Treatment with 3′-Fluorothymidine

  1992cited by this paper
• Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection

  1992cited by this paper
• Clinical features and predictive markers of disease progression in cynomolgus monkeys experimentally infected with simian immunodeficiency virus

  1992cited by this paper
• The Use of SIV-Infected Rhesus Monkeys for the Preclinical Evaluation of AIDS Drugs and Vaccines

  1992cited by this paper
• Early appearance of simian immunodeficiency virus (SIV) antigen and antibodies as variables in evaluating antiviral drugs in macaques.

  1992cited by this paper
• Influence of the Infectious Dose of Simian Immunodeficiency Virus on the Acute Infection in Cynomolgus Monkeys and on the Effect of Treatment with 3′-Fluorothymidine

  1992cited by this paper
• A capture enzyme immunoassay for detection of HIV-2/SIV antigen.

  1991cited by this paper
• On the chemistry of the reaction between N-acetylcysteine and 4-[(4-ethoxyphenyl)imino]-2,5-cyclohexadien-1-one, a 4-ethoxyaniline metabolite formed during peroxidase reactions.

  1991cited by this paper
• Synthesis of 2',3'-dideoxy-3'-C-hydroxymethyl nucleosides as potential inhibitors of HIV

  1991cited by this paper
• Vaccine Protection Against HIV-2 Infection in Cynomolgus Monkeys

  1991cited by this paper
• Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.

  1991cited by this paper
• Synthesis and Antiviral Evaluation of 3′-Branched Nucixoside Analogues

  1991cited by this paper
• Treatment of Acute SIV infection in cynomolgus Monkeys with 2′,3′-dideoxyinosine (ddl) and 2′,3′-dideoxythymidiene (d4T)

  1991cited by this paper
• Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus.

  1991cited by this paper
• Acute Infection of Cynomolgus Monkeys with Simian Immunodeficiency Virus (SIVSM) as a Model to Evaluate Antiviral Compounds. Effects of 3′-Azido, 3′-Deoxythymidine, Foscarnet and 2′,3′-Dideoxycytidine

  1990cited by this paper
• Nonhuman Primate Models for Evaluation of AIDS Therapy a

  1990cited by this paper

• Updated guidelines on HIV post‐exposure prophylaxis: continued efforts towards increased accessibility

  2024cites this paper
• Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection

  2020cites this paper
• Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection

  2020cites this paper
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

  2020cites this paper
• Evaluation and Management of the Infant Exposed to HIV in the United States

  2020cites this paper
• Knowledge, Attitude, and Practice of Postexposure Prophylaxis against HIV Infection among Healthcare Workers in Hiwot Fana Specialized University Hospital, Eastern Ethiopia

  2019cites this paper
• The Link Between HIV Knowledge and Prophylaxis to Health Professionals

  2019cites this paper
• Effectiveness of PEP in Preventing Occupational HIV Infection

  2019cites this paper
• British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018

  2019cites this paper
• Efficacy of HIV Pre Exposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies

  2017cites this paper
• Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study

  2015cites this paper
• Occupational Exposures among Healthcare Workers: New Methods for Prevention and Recommended Postexposure Prophylaxis for HIV and Hepatitis B and C

  2015cites this paper
• 307 – Human Immunodeficiency Virus in Health Care Settings

  2015cites this paper
• Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies.

  2015cites this paper
• Accidentes ocupacionales de riesgo biológico en Antioquia, Colombia. Enero de 2010 a diciembre de 2011

  2014cites this paper
• Guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)

  2014cites this paper
• British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)

  2014cites this paper
• Scientific Committee on AIDS and STI ( SCAS ) Using Antiretrovirals for Post Exposure Prophylaxis against HIV in the Non-occupational Setting – Position Statement of the SCAS

  2013cites this paper
• Pediatric AIDS

  2013cites this paper
• Post‐exposure prophylaxis in resource‐poor settings: review and recommendations for pre‐departure risk assessment and planning for expatriate healthcare workers

  2013cites this paper
• 5.0 Use of antiretroviral therapy in pregnancy

  2012cites this paper
• 2.0 Recommendations and auditable outcomes

  2012cites this paper
• 8.0 Neonatal management

  2012cites this paper
• Appendix 4

  2012cites this paper
• 7.0 Obstetric management

  2012cites this paper
• 4.0 Screening and monitoring of HIV‐positive pregnant women

  2012cites this paper
• Appendix 2: Systematic literature search

  2012cites this paper
• Needlesticks injuries in dentistry.

  2012cites this paper
• Management of needlestick injuries: a house officer who has a needlestick.

  2012cites this paper
• Evaluating HIV treatment as prevention in the European context.

  2012cites this paper
• Appendix 3 Search protocols (main databases search)

  2012cites this paper
• Appendix 1: Summary of the modified GRADE system

  2012cites this paper
• The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

  2012cites this paper
• Guidelines for the management of HIV infection in pregnant women 2012

  2012cites this paper
• 3.0 Introduction

  2012cites this paper
• 11.0 References

  2012cites this paper
• Safety in the Working Environment– The Place of Post Exposure Prophylaxis against HIV Infection. -

  2010cites this paper
• Occupational Blood Borne Infections: Prevention is Better than Cure

  2010cites this paper
• Evaluation of antiretrovirals in animal models of HIV infection.

  2010cites this paper
• Italian consensus statement on paediatric HIV infection

  2010cites this paper
• Issues of prematurity and HIV infection.

  2010cites this paper
• Evaluation and Management of the Infant Exposed to HIV-1 in the United States

  2009cites this paper
• Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture

  2009cites this paper
• Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir

  2009cites this paper
• Convenient syntheses of 3'-amino-2',3'-dideoxynucleosides, their 5'-monophosphates, and 3'-aminoterminal oligodeoxynucleotide primers.

  2009cites this paper
• Human Immunodeficiency Virus

  2009cites this paper
• HIV-Infected Patients: The Risks of Surgery

  2009cites this paper
• Postexpositionelle Prophylaxe der HIV-Infektion

  2009cites this paper
• Significant Virus Replication in Langerhans Cells following Application of HIV to Abraded Skin: Relevance to Occupational Transmission of HIV1

  2008cites this paper
• Occupational exposure to HIV and the use of post-exposure prophylaxis.

  2007cites this paper
• The Risks of Surgery in HIV-Infected Patients

  2007cites this paper
• Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.

  2007cites this paper
• Human immunodeficiency virus postexposure prophylaxis for occupational exposure in a medical school hospital in Thailand.

  2007cites this paper
• Cost-effectiveness of HIV post-exposure prophylaxis in France

  2006cites this paper
• SIV Infection of Macaques as a Model for AIDS Drug Studies

  2006cites this paper
• The uptake of HIV post-exposure prophylaxis within a sexual assault setting in Sydney, Australia

  2005cites this paper
• HIV post-exposure prophylaxis (PEP) after occupational and non-occupational exposure☆

  2005cites this paper
• Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments.

  2005cites this paper
• Postexpositieprofylaxe na blootstelling aan HIV: aanpassing aan de situatie kan gendiceerd zijn

  2005cites this paper
• ICE volume 26 issue 9 Front matter

  2005cites this paper
• Antiretroviral Drug Resistance Among Patients With Human Immunodeficiency Virus Who Act as Sources or Potential Sources in Occupational Accidents Involving Healthcare Workers

  2005cites this paper
• Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children.

  2004cites this paper
• Guidance for the Clinician in Rendering Pediatric Care Evaluation and Treatment of the Human Immunodeficiency Virus-1 – Exposed Infant

  2004cites this paper
• Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.

  2004cites this paper
• Offering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures Recommendations for Health Care Providers in the State of California

  2004cites this paper
• Evaluation and treatment of the human immunodeficiency virus-1--exposed infant.

  2004cites this paper
• AMERICAN ACADEMY OF PEDIATRICS

  2004cites this paper
• Deutsch-Österreichische Leitlinien zur postexpositionellen Prophylaxe der HIV-Infektion

  2003cites this paper
• New guidelines for occupational exposure to blood-borne viruses.

  2003cites this paper
• [German-Austrian guidelines for postexposure prophylaxis of HIV infection. (May, 2002, update)].

  2003cites this paper
• Clinical practice. Occupational exposure to HIV in health care settings.

  2003cites this paper
• Occupational Exposure to HIV in Health Care Settings

  2003cites this paper
• Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251.

  2003cites this paper
• Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to reduce Perinatal HIV-1Transmission in the United States

  2003cites this paper
• Guidance for the Clinician in Rendering Pediatric Care

  2003cites this paper
• U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

  2002cites this paper
• Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 – Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States *

  2002cites this paper
• [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].

  2002cites this paper
• Postexposure Prophylaxis for Occupational Exposure and Sexual Assault

  2002cites this paper
• Post-exposure prophylaxis

  2002cites this paper
• Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians’ experiences and attitudes

  2002cites this paper
• Sex differences in nevirapine rash.

  2001cites this paper
• Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.

  2001cites this paper
• Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.

  2001cites this paper
• HIV postexposure prophylaxis in the 21st century.

  2001cites this paper
• Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United StatesRevised November 3, 2000

  2001cites this paper
• SURGEON AND HIV INFECTION, POST EXPOSURE PROPHYLAXIS: NEED OF THE HOUR.

  2001cites this paper
• Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States Perinatal HIV Guidelines Working Group Members

  2001cites this paper
• Tolerability of Postexposure Antiretroviral Prophylaxis for Occupational Exposures to HIV

  2001cites this paper
• Emerging viral infections

  2001cites this paper
• Prophylaxis against possible human immunodeficiency virus exposure after nonoccupational needlestick injuries or sexual assaults in children and adolescents.

  2001cites this paper
• US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States, February 25, 2000.

  2000cites this paper
• Management of HIV-infected children in the home and institutional settings. Care of children and infections control in schools, day care, hospital settings, home, foster care, and adoption.

  2000cites this paper
• Nonoccupational HIV Postexposure

  2000cites this paper
• Pharmacologic management of HIV/STD exposure.

  2000cites this paper
• Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States Perinatal HIV Guidelines Working Group Members

  2000cites this paper
• Postexposure to HIV prophylaxis.

  2000cites this paper
• Emergency department management of blood and body fluid exposures.

  2000cites this paper
• Re: Emergency Department management of occupational exposures to HIV-infected fluids.

  2000cites this paper
• Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2)

  2000cites this paper